4521 — Kaken Pharmaceutical Co Balance Sheet
0.000.00%
- ¥149bn
- ¥96bn
- ¥94bn
- 72
- 41
- 35
- 48
Annual balance sheet for Kaken Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Yuho | Yuho | Yuho | Yuho | Yuho |
| Standards: | JAS | — | — | — | JAS |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 77,305 | 74,624 | 74,260 | 65,324 | 70,085 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 20,549 | 20,260 | 19,268 | 23,744 | 21,178 |
| Total Inventory | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 113,662 | 110,613 | 109,903 | 106,974 | 111,377 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 25,020 | 25,734 | 25,498 | 25,355 | 27,629 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 163,332 | 165,181 | 166,328 | 171,623 | 190,422 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 21,276 | 19,049 | 20,838 | 19,024 | 30,354 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 27,075 | 27,434 | 30,070 | 27,868 | 37,788 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Treasury Stock | |||||
| Unrealized Gain / Loss | |||||
| Other Equity | |||||
| Total Equity | 136,257 | 137,747 | 136,258 | 143,755 | 152,634 |
| Total Liabilities & Shareholders' Equity | 163,332 | 165,181 | 166,328 | 171,623 | 190,422 |
| Total Common Shares Outstanding |